The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review

Abstract

Diabetes mellitus (DM) is one of the fastest growing diseases in terms of global incidence and seriously affects cognitive function. The incidence rate of cognitive dysfunction is up to 13% in diabetes patients aged 65–74 years and reaches 24% in those aged >75 years. The mechanisms and treatments of cognitive dysfunction associated with diabetes mellitus are complicated and varied. Previous studies suggest that hyperglycemia mainly contributes to cognitive dysfunction through mechanisms involving inflammation, autophagy, the microbial-gut-brain axis, brain-derived neurotrophic factors, and insulin resistance. Antidiabetic drugs such as metformin, liraglutide, and empagliflozin and other drugs such as fingolimod and melatonin can alleviate diabetes-induced cognitive dysfunction. Self-management, intermittent fasting, and repetitive transverse magnetic stimulation can also ameliorate cognitive impairment. In this review, we discuss the mechanisms linking diabetes mellitus with cognitive dysfunction and propose a potential treatment for cognitive decline associated with diabetes mellitus.

Keywords

cognitive dysfunction - diabetes - mechanism - treatment

Introduction

Diabetes mellitus (DM) is one of the most common chronic diseases occurring globally and is estimated to affect 693 million adults by 2045 [1]. It is associated with deficits in different cognitive areas and specifically contributes to accelerating cognitive decline [2]. Cognitive dysfunction includes mild cognitive impairment (MCI) and dementia [3]. Diabetic cognitive dysfunction (DCI) is one of the common complications of diabetes and mainly manifests as the loss of learning ability and memory and behavioral disorders [4], which have a serious influence on the quality of life [5]. It is difficult to reverse DCI once it occurs, and DCI can even develop into dementia [6]. Studies have indicated that diabetes is closely associated with cognitive dysfunction [7] [8] [9] [10] [11]. In general, cognitive impairment cannot be easily detected in the early stages but may gradually impair the ability to perform activities of daily life [12]. Studies have shown that in the majority of cases, the development of cognitive dysfunction in patients with diabetes is strongly related to age [13]. Cognitive decline can be aggravated in patients with diabetes and can even develop into MCI and dementia [14]. The occurrence of MCI was found to be related to long-term hyperglycemia [15]. Research has shown that the prevalence of cognitive dysfunction is up to 13% in diabetes patients aged 65–74 and reaches 24% in those aged over 75 years [16]. In a cohort study with a follow-up of 31.7 years, the findings demonstrated that at an early onset diabetes significantly increased the possibility of developing dementia. For every five years earlier the onset of diabetes was, the likelihood of dementia markedly increased. Conversely, no significant association was observed between late-onset diabetes and the subsequent development of dementia [17]. The characteristics of diabetes-related cognitive dysfunction vary in different stages, and the mechanisms are distinct. The mechanisms underlying diabetes-related cognitive dysfunction are complex and diverse, posing challenges in the treatment of this condition; moreover, a comprehensive discussion of the mechanisms of and therapies for diabetes-related cognitive dysfunction is lacking. This review aims to summarize the mechanisms of and therapies for diabetes-related cognitive dysfunction and provide a basis for the treatment of diabetes-related cognitive dysfunction.

Mechanisms of cognitive dysfunction related to diabetes mellitus

Inflammation

Substantial evidence has shown that inflammation is involved in the occurrence of diabetes-related cognitive dysfunction [18] [19] [20]. Chronic hyperglycemia can activate the NOD-like receptor protein 3 inflammasome (NLRP3) and induce the inflammatory cascade, resulting in cognitive dysfunction [6]. Inhibition of NLRP3 in the brain can alleviate cognitive dysfunction in diabetic rats [21]. Microglia are immune cells in the brain that act as important regulators of neuroinflammation. Diabetes-related cognitive decline is associated with apoptosis of hippocampal neurons and microglia caused by microglial activation, with neuroinflammation caused by the overactivation of microglia being a major neuropathological feature of this condition [22] [23]. Hyperglycemia can easily lead to the dysfunction of glycolipid metabolism and aggravate the pathological microglia reactivity. The sterol regulatory element-binding protein cleavage activating protein (SCAP) increases NLRP3 expression and the release of inflammatory factors, thus aggravating the development progression of cognitive dysfunction [24]. Microglia are macrophages in the central nervous system. Various stimuli, such as cytokines, endotoxins, and hyperglycemia, can activate microglia, causing them to secrete inflammatory cytokines and remove debris during the central inflammatory response. Microglia express phosphoinositide 3-kinase (PI3K), which plays an important role in synaptic plasticity and inflammation through microglia. Increased activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway is involved in the regulation of oxidative stress, neuroinflammation, synaptic cell plasticity, apoptosis, etc. The brain-derived neurotrophic factor (BDNF) signaling pathway in microglia is also regulated by the PI3K/AKT pathway [25]. Microglia can be polarized toward two different phenotypes, the classical M1 phenotype and the alternative M2 phenotype [26]. M1 polarization of microglia exerts a proinflammatory effect by promoting the production of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6). M2 polarization of microglia exerts an anti-inflammatory effect by promoting the phagocytosis of cellular debris or damaged neurons and the secretion of anti-inflammatory cytokines, such as IL-4 and IL-10 [27]. Whether microglia are polarized toward the proinflammatory or anti-inflammatory phenotype depends on the surrounding immune environment. Regulatory T cells (Tregs) play an important role in this process by exerting anti-inflammatory, immunosuppressive, and neuroprotective effects. Treg function is linked with microglial polarization in the brain. Impaired Tregs polarize microglia towards a proinflammatory phenotype, which subsequently leads to neuroinflammation and diabetes-related cognitive dysfunction [28] [29].

Autophagy

Autophagy is a process of intracellular lysosomal catabolism and metabolism that regulates protein homeostasis and organelle turnover. Autophagy is also an intracellular degradation pathway that maintains intracellular homeostasis by removing damaged organelles, pathogens, and unwanted protein aggregates [30]. The hippocampus plays a key role in the regulation of learning and memory, and autophagy in hippocampal neurons improves memory and cognitive function [31]. Autophagy can modulate microglial activation, and in cellular and animal models, autophagy has been shown to contribute to different aspects of neuronal and microglial physiology, such as axonal homeostasis, synaptic repair, and neurogenesis. Diabetes-associated cognitive decline is connected with neuroinflammation and apoptosis of hippocampal neurons and microglia caused by microglial activation, which may be due to the suppression of autophagy [22]. As autophagy levels increase, cognitive function improves [6]. Autophagy also assists in the clearance of cytotoxic proteins accumulated in the brain. LC3B-II, ATG5, ATG7, and P62 are involved in the initiation and maintenance of autophagosome formation. In diabetes-related cognitive dysfunction, the expression of LC3BII, ATG5, and ATG7 is upregulated, while that of P62 is downregulated in the hippocampus, which suggests a protective effect of autophagy against diabetes-related cognitive dysfunction to a certain degree [32].

Microbe-gut-brain axis

Cognitive dysfunction is an important comorbidity of diabetes [5] [14] [33]. Gut microbes have a symbiotic relationship with their hosts; they digest exogenous and indigestible foods, produce secondary metabolites that can affect host physiology, and metabolize endogenous substrates during prolonged fasting [34]. The gut microbiota is an emerging target for managing diabetes and maintaining cognitive function [35]. Signals can be transmitted via the microbe-gut-brain axis through multiple mechanisms. The production of pro- and anti-inflammatory cytokines is influenced by the gut flora, and these cytokines send signals to the brain through the circulatory system [36]. The gut-brain axis is a complex bidirectional communication system between the gastrointestinal tract and the central nervous system involving the endocrine, immune, and nervous systems [37]. The gut microbe metabolite acetate plays an important role in regulating cognitive function through the gut-brain axis. Synaptophysin, a synaptic vesicle membrane protein, affects the efficiency of synaptic vesicle cycling, the disruption of which impairs cognitive ability. Acetate from microorganisms can modulate hippocampal synaptophysin levels by stimulating the vagus nerve, which in turn improves cognitive function. Chronic acetate deficiency can result in a reduction in hippocampal synaptophysin levels and consequent cognitive decline [38]. Akkermansia muciniphila, a gut microbe, downregulates proinflammatory cytokines, especially IL-6 in the peripheral blood and hippocampus, and this change is correlated with improved cognitive function. An anti-IL-6 antibody was found to protect cognitive function in aged mice; however, the recombinant IL-6 protein was shown to abrogate the protective effect of Listeria monocytogenes on cognitive function [39].

Insulin resistance

Insulin resistance is strongly associated with diabetes-related cognitive dysfunction [12] [40]. Insulin acts in the central nervous system and regulates behavior and metabolism, which are associated with cognitive function [16] [41]. Insulin regulates various biological processes by binding to and activating insulin receptors such as tyrosine kinase receptors [42]. Upon binding of insulin to an insulin receptor, the insulin receptor substrate (IRS) protein is activated, triggering the PI3K/AKT cascade, which plays a neuroprotective role in the brain, especially in the hippocampus [43]. During insulin resistance, the inability of the pancreas to supply adequate amounts of insulin results in a marked disruption of systemic glucose homeostasis, which is characterized by hyperglycemia and glucose intolerance (in the case of both impaired fasting glucose and impaired glucose tolerance) [44]. Insulin signaling pathways are primarily inactivated by serine phosphorylation of insulin receptors, which inhibits the PI3K/AKT signaling cascade and prevents glucose transporter protein 4 transport, in turn causing the overproduction of advanced glycation end products (AGEs) during hyperglycemia and leading to reduced cerebral blood flow. Reduced cerebral blood flow leads to vascular barrier disruption and consequent cognitive dysfunction. Insulin can cross the blood-brain barrier and play an important role in the regulation of central nervous system function; therefore, it has a significant effect on cognitive processes [45] [46]. In addition, insulin resistance affects mitochondrial function, leading to decreased ATP production and increased oxidative stress, which cause mitochondrial dysfunction, activation of inflammatory responses[40] [47], and ultimately cognitive dysfunction.

Brain-derived neurotrophic factor (BDNF)

BDNF is a member of the neurotrophic factor family and plays a key role in neuronal differentiation and growth, as well as synaptic connectivity [48]. A low BDNF level is associated with diabetes-related cognitive dysfunction, while its elevated levels can improve cognitive function [49]. In the central nervous system, BDNF is abundantly expressed in the hippocampus, where it is associated with memory and cognition. It increases neuroplasticity and neurogenesis through its cognate tyrosine kinase receptor TrkB [50]. However, AGEs can inhibit the BDNF-TrkB pathway in T2DM [51], nullifying this compensatory neuroprotective effect and rendering patients with T2DM more susceptible to neurodegeneration, ultimately resulting in impaired cognitive function.

Fig. 1 A flowchart of cognitive dysfunction in diabetes mellitus.

Oxidative stress

Oxidative stress is closely associated with diabetes-related cognitive dysfunction [52] [53] [54]. In normal cell metabolism, glucose oxidation is the most common source of energy production [55], and oxidative stress is prone to occur when oxidants and antioxidants are out of balance. Hyperglycemia reduces antioxidant levels and increases the production of free radicals. Oxidative stress results in high oxygen consumption, and reactive oxygen species (ROS) produced in response to hyperglycemia disrupts antioxidant homeostasis in the brain, thus causing brain tissue cell damage [56] [57]. Diabetes increases oxidative stress, levels of ROS, lipid peroxide, and NADPH oxidase, and inhibits the hippocampal Nrf2/HO-1/ NQO1 signaling pathway to further decrease antioxidant capacity[58]. Oxidative stress increases the activity of acetylcholinesterase [57] and impairs the plasticity of neurons and synapses [59]. Oxidative stress also increases the production of mitochondrial ROS, reduces the levels of antioxidant SOD and GSH, and causes non-enzymatic glycosylation of proteins and glucose oxidation [60]. Through the above mechanisms, cognitive dysfunction can develop in diabetic patients.

Diabetic Neurodegeneration

Diabetic neurodegeneration can affect brain structure and function, resulting in cognitive dysfunction. Cognitive function relies on the communication between neurons through synapses [61]; however, morphological and structural changes in brain neurons have been observed in experimental animal models of diabetes mellitus [62]. In different stages of the disease, neurons show varying signs of degeneration, such as cell body enlargement, nuclear enlargement, a reduction in the number of organelles, mitochondrial swelling, endoplasmic reticulum expansion, fracture and vacuole formation, and increased plasma electron density in axons and dendrites [62]. Moreover, patients with diabetes-related cognitive decline may have severe and diffuse degeneration of grey matter, white matter, and neurons [63]. The firing of action potentials and the release and recycling of neurotransmitters in the brain require high levels of energy [63] [64]. Microvascular and macrovascular diseases in diabetic patients may lead to reduced blood flow to the brain, which in turn affects the energy supply to brain tissue and impairs nerve function. During the degeneration of the central nervous system in patients with diabetes, areas of the brain closely related to cognitive function, such as the hippocampus, are severely damaged [65] [66]. The hippocampus is a key brain region for learning and memory, and electrophysiological studies have shown that diabetes reduces synaptic plasticity in areas of the hippocampus, which affects cognitive functions such as memory, learning, and attention.

Pharmacological treatment of diabetes-related cognitive dysfunction

Hypoglycemic agents

Metformin

Discovered 300 years ago in a traditional herbal medicine, metformin was redeveloped in the 1940s as an antimalarial drug [67]. The use of metformin in the treatment of diabetes was first reported by French physician Jean Sterne in 1957; after rigorous scrutiny, metformin was approved for use in the United States in 1995 [68]. Metformin improves cognitive function through multiple mechanisms [69] [70]. Metformin induces the polarization of microglia to the beneficial anti-inflammatory M2 phenotype, reduces the formation of pathologic microglial clusters, decreases proinflammatory cytokine levels, and increases autophagy in the hippocampus, thus improving cognitive function [71]. It is also able to improve cognitive function by increasing insulin sensitivity [47]. Samaras et al. [72] showed that older patients with diabetes treated with metformin had slower cognitive decline and a lower risk of dementia. Metformin has been shown to decrease the α diversity of gut bacteria and increase the abundance of Lactobacillus mucilaginous, L. royale, L. salivarius, and Bacillus paracasei, which decreases with age. Metformin-mediated production of A. muciniphila was shown to improve cognitive function in aged mice by modulating host inflammation-related pathways through a reduction in the level of the proinflammatory cytokine IL-6 [39]. Metformin can also increase BDNF levels in the brain, thereby improving cognitive function [73].

Glucagon-like peptide-1 (GLP-1)

GLP-1 receptor agonists (GLP-1RAs) improve vascular, microglial, and neuronal function [74]. They exert neuroprotective effects by attenuating neuroinflammation and modulating the PI3K/AKT pathway [75] [76]. Liraglutide, a GLP-1 analog [77] [78] [79] with 97% homology to human GLP-1, was shown to inhibit inflammatory factor (e. g., TNF-α, IL-1β, and IL-10) production [80] and attenuate neuroinflammation [81]. Liraglutide was found to attenuate neuronal and synaptic ultrastructure damage in the CA1 region of the hippocampus. Furthermore, liraglutide promotes the expression of the autophagy markers microtubule-associated protein 1 light chain 3 (LC3)-II and beclin 1. In vitro, liraglutide increases the level of phosphorylated AMP-activated protein kinase (p-AMPK) and decreases the level of phosphorylated mammalian target of rapamycin (p-mTOR). Liraglutide promotes autophagy through the AMPK/mTOR pathway [82], suggesting its potential in promoting autophagy in diabetic mice, in turn ameliorating cognitive decline [82] [83].

Sodium-glucose cotransporter 2 (SGLT2)

SGLT2 inhibitors are relatively new hypoglycemic agents with anti-inflammatory properties that increase macrophage polarization, inhibit NLRP3 inflammasome activation [84], and ameliorate cognitive dysfunction [85]. Engeletin could significantly increase BDNF levels in the brain, leading to the improvement of cognitive function [84] [86]. Engeletin was also shown to protect microglia and improve cognitive function [87]. Furthermore, engeletin can block nuclear factor (NF)-κB, c-Jun N-terminal kinase (JNK) and signal transducers and activators of transcription 1 and 3 (STAT1/3) phosphorylation through the IκB kinase/NF-κB, mitogen-activated protein kinase 7/JNK, and Janus kinase 2/STAT1 pathways, exerting an anti-inflammatory effect to improve cognitive function [88].

Nonglycemic agents

Fingolimod

Sphingosine receptors (S1PRs) are associated with the progression of neurodegenerative diseases. Neuroinflammation is a common pathology of T2DM and cognitive impairment. Inhibition of S1P1 activity decreases the phosphorylation of the M1 markers extracellular signal-regulated kinase 1/2, p38, and JNK MAPKs but increases the phosphorylation of M2 marker AkT; these molecules participate in pathways downstream of S1P1 activation [89]. Fingolimod (an S1PR1 modulator) reduces microglial polarization and ameliorates cognitive dysfunction [90] [91]. Studies indicate that that fingolimod ameliorates cognitive deficits by modulating microglial polarization in T2DM through the inhibition of proinflammatory cytokine production [92].

Melatonin (MLT)

MLT is a major secretory product of the pineal gland that can improve cognitive function [93] [94]. MLT has been shown to inhibit microglial cell activation and reduce the levels of proinflammatory cytokines. In one study, MLT could significantly reduce the levels of toll-like receptor 4 (TLR4), p-Akt, and mTOR, suggesting that blockade of the TLR4/Akt/mTOR pathway may be a potential mechanism underlying the anti-inflammatory and anti-apoptotic effects of MLT. MLT reduces plasma insulin levels, restores peripheral insulin sensitivity, and ameliorates insulin resistance, thus normalizing blood glucose levels and consequently improving cognitive function [95]. It could also reduce the levels of TLR4, p-Akt, and p-mTOR in the hippocampus of T2DM mice through the TLR4/Akt/mTOR pathway, thus promoting cell autophagy and improving cognitive function [22]. In addition, MLT restores mitochondrial autophagy and improves cognitive function by reversing aberrant expression of lysosomal signaling pathway proteins and pathological phagocytosis of microglia and facilitating the fusion of autophagosomes with lysosomes via Mcoln1 [96].

Nonpharmacologic treatment of diabetes-related cognitive dysfunction

Self-management

Basic personal care activities require less cognitive capacity than complex instrumental activities of daily living, such as self-management of diseases, which is among the activities that allow for independent living in the community. Self-management of diabetes requires proper planning as well as correct and timely execution of tasks such as blood glucose monitoring, taking regular medication regularly, modifying diet and lifestyle, and establishing appropriate blood glucose levels [97]. In a 2018 systematic review of eight studies, 64 types of executive dysfunction, memory impairment, and learning deficits were associated with poor self-management in patients with diabetes-related cognitive dysfunction and dementia. Poor self-management of the disease was directly correlated with worse cognitive dysfunction in these patients [98]. Another systematic review showed that developing the right attitude towards self-management of diabetes is effective in improving cognitive function [99]. These results highlight the importance of self-management in the treatment of diabetes-related cognitive dysfunction.

Intermittent fasting (IF)

IF is a cyclical diet that has become very popular for its ability to reduce weight [100] and potentially improve memory [101] [102]. IF alters T cells in the gut, resulting in a decrease in the production of inflammatory cells and an increase in the number of regulatory T cells; IF also leads to an increase in intestinal bacterial abundance and activation of microbial metabolic pathways that regulate systemic immune responses [103]. IF can improve cognitive function by: (1) reversing the disruption of the intestinal barrier and the changes in the intestinal microbiome caused by diabetes mellitus, thereby improving the integrity of the intestinal tract and the intestinal barrier [34], and also reducing plasma LPS levels, in turn inhibiting the neuroinflammatory response; (2) increasing insulin sensitivity in mice by decreasing fasting blood glucose and fasting insulin levels; (3) inhibiting NF-κB activation, decreases JNK/p38 phosphorylation and downregulates the expression of Iba-1, a well-known marker of microglial activation, and attenuating inflammatory responses; and (4) altering the microbial diversity in diabetic mice by increasing the abundance of Lactobacilli and reorganizing the intestinal microbiota, leading to alterations in the serum levels of microbial metabolites and consequently alleviating cognitive dysfunction associated with diabetes through the gut-brain axis [104].

Repetitive transcranial magnetic stimulation

Brain stimulation is currently considered a highly effective treatment for cognitive dysfunction. Noninvasive brain stimulation has a significant effect on cognition [105]. One such method, repetitive transcranial magnetic stimulation (rTMS), is an evolving noninvasive brain stimulation technique [106] [107] that is effective in improving cognitive function [108] [109]. A meta-analysis showed that noninvasive brain stimulation such as rTMS can transiently and noninvasively modulate neuronal activity and cortical excitability, thus improving cognitive function [110] [111]. High-frequency rTMS of the left dorsolateral prefrontal cortex and right dorsolateral prefrontal cortex improves memory capacity through activation of BDNFs, and the high-frequency rMTS of the right inferior frontal gyrus increases executive capacity [112]. TMS at 20 Hz effectively reduces microglial activation through the PI3K/Akt/NF-κB signaling pathway and decreases the levels of proinflammatory cytokines (such as IL-6 and TNF-α), thus relieving neuroinflammation, neuronal loss, apoptosis, and improving synaptic plasticity and cognitive function in mice [113] [114].

Conclusions

Diabetes-related cognitive dysfunction is a serious complication of diabetes that imposes a heavy burden on families and society. It also poses a challenge to healthcare systems and affects socioeconomic status. Understanding the mechanism underlying diabetes-related cognitive impairment is a prerequisite for its treatment. This review explores the mechanisms of and treatments for diabetes-related cognitive dysfunction to provide a basis for clinicians to better treat diabetes-related cognitive dysfunction.

Data availability statement

The data is available on request from the authors.

Conflict of Interest

The authors declare that they have no conflict of interest.

• References

• 1 Cho NH, Shaw JE, Karuranga S. et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281
• 2 Marseglia A, Fratiglioni L, Kalpouzos G. et al. Prediabetes and diabetes accelerate cognitive decline and predict microvascular lesions: A population-based cohort study. Alzheimers Dement 2019; 15: 25-33
• 3 Biessels GJ, Verhagen C, Janssen J. et al. Effect of linagliptin on cognitive performance in atients with type 2 diabetes and cardiorenal comorbidities: The CARMELINA Randomized Trial. Diabetes Care 2019; 42: 1930-1938
• 4 Nie R, Lu J, Xu R. et al. Ipriflavone as a non-steroidal glucocorticoid receptor antagonist ameliorates diabetic cognitive impairment in mice. Aging Cell 2022; 21: e13572
• 5 Biessels GJ, Whitmer RA. Cognitive dysfunction in diabetes: How to implement emerging guidelines. Diabetologia 2020; 63: 3-9
• 6 Tian R, Liu X, Jing L. et al. Huang-Lian-Jie-Du decoction attenuates cognitive dysfunction of rats with type 2 diabetes by regulating autophagy and NLRP3 inflammasome activation. J Ethnopharmacol 2022; 292: 115196
• 7 Rawlings AM, Sharrett AR, Albert MS. et al. The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: The ARIC Study. Diabetes Care 2019; 42: 1248-1254
• 8 Xue M, Xu W, Ou YN. et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev 2019; 55: 100944
• 9 van Sloten TT, Sedaghat S, Carnethon MR. et al. Cerebral microvascular complications of type 2 diabetes: Stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol 2020; 8: 325-336
• 10 Yu JH, Kim REY, Park SY. et al. Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study. Diabetes Obes Metab 2023; 25: 1091-1100
• 11 Grieco M, Giorgi A, Gentile MC. et al. glucagon-like peptide-1: A focus on neurodegenerative diseases. Front Neurosci 2019; 13: 1112
• 12 Bao H, Liu Y, Zhang M. et al. Increased β-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment. Alzheimers Dement 2021; 17: 1097-1108
• 13 Arpita C, Sumukha H, Samir KP. et al. Age related prevalence of mild cognitive impairment in type 2 diabetes mellitus patients in the Indian population and association of serum lipids with cognitive dysfunction. 2022; 12
• 14 Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. Nat Rev Endocrinol 2018; 14: 591-604
• 15 Roberts RO, Knopman DS, Geda YE. et al. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimer Dementia 2014; 10: 18-26
• 16 Cukierman-Yaffe T, Gerstein HC, Colhoun HM. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial. Lancet Neurol 2020; 19: 582-590
• 17 Barbiellini Amidei C, Fayosse A, Dumurgier J. et al. Association between age at diabetes onset and subsequent risk of dementia. JAMA 2021; 325: 1640-1649
• 18 Anniek JS, Stela M, Rachel BF. et al. Higher baseline inflammatory marker levels predict greater cognitive decline in older people with type 2 diabetes: Year 10 follow-up of the Edinburgh Type 2 Diabetes Study. 2021; 65
• 19 Yage D, Qi Z, Xiaolan Z. et al. Correlation between inflammatory biomarkers, cognitive function and glycemic and lipid profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Clin Biochem 2023; 110683
• 20 Adam HD, Louise M, Isabella B. et al. Peripheral inflammation and cognitive performance in middle-aged adults with and without type 2 diabetes: Results from the ENBIND Study. Front Aging Neurosci 2021; 12: 605878
• 21 Liu P, Li H, Wang Y. et al. Harmine ameliorates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF/TrkB signaling pathway in STZ-induced diabetic rats. Front Pharmacol 2020; 11: 535
• 22 Cui Y, Yang M, Wang Y. et al. Melatonin prevents diabetes-associated cognitive dysfunction from microglia-mediated neuroinflammation by activating autophagy via TLR4/Akt/mTOR pathway. FASEB J 2021; 35: e21485
• 23 Qing L, Yujing Z, Hongyan G. et al. Impaired lipophagy induced-microglial lipid droplets accumulation contributes to the buildup of TREM1 in diabetes-associated cognitive impairment. Autophagy 2023; 19
• 24 Wenwen Z, Haoqiang Z, Tong N. et al. Microglial SCAP deficiency protects against diabetes-associated cognitive impairment through inhibiting NLRP3 inflammasome-mediated neuroinflammation. Brain Behav Immun 2024; 119: 154-170
• 25 Saw G, Krishna K, Gupta N. et al. Epigenetic regulation of microglial phosphatidylinositol 3-kinase pathway involved in long-term potentiation and synaptic plasticity in rats. Glia 2020; 68: 656-669
• 26 Liu W, Li K, Zheng M. et al. Genipin attenuates diabetic cognitive impairment by reducing lipid accumulation and promoting mitochondrial fusion via FABP4/Mfn1 signaling in microglia. Antioxidants 2023; 12: 74
• 27 Cheng J, Liao Y, Dong Y. et al. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy 2020; 16: 2193-1205
• 28 Hui Y, Xu Z, Li J. et al. Nonenzymatic function of DPP4 promotes diabetes-associated cognitive dysfunction through IGF-2R/PKA/SP1/ERp29/IP3R2 pathway-mediated impairment of Treg function and M1 microglia polarization. Metabolism 2023; 138: 155340
• 29 Machhi J, Kevadiya BD, Muhammad IK. et al. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener 2020; 15: 32
• 30 Cheng LZ, Li W, Chen YX. et al. Autophagy and diabetic encephalopathy: Mechanistic insights and potential therapeutic implications. Aging Dis 2022; 13: 447-457
• 31 Glatigny M, Moriceau S, Rivagorda M. et al. Autophagy is required for memory formation and reverses age-related memory decline. Curr Biol 2019; 29: 435-448.e8
• 32 Wu Y, Ye L, Yuan Y. et al. Autophagy activation is associated with neuroprotection in diabetes-associated cognitive decline. Aging Dis 2019; 10: 1233-1245
• 33 Janssen J, van den Berg E, Zinman B. et al. HbA(1c), insulin resistance, and β-cell function in relation to cognitive function in type 2 diabetes: The CAROLINA Cognition Substudy. Diabetes Care 2019; 42: e1-e3
• 34 Beli E, Yan Y, Moldovan L. et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes 2018; 67: 1867-1879
• 35 Guzzardi MA, La Rosa F, Iozzo P. Trust the gut: Outcomes of gut microbiota transplant in metabolic and cognitive disorders. Neurosci Biobehav Rev 2023; 149: 105143
• 36 Long-Smith C, O'Riordan KJ, Clarke G. et al. Microbiota-gut-brain axis: New therapeutic opportunities. Annu Rev Pharmacol Toxicol 2020; 60: 477-502
• 37 Fülling C, Dinan TG, Cryan JF. Gut microbe to brain signaling: What happens in vagus. Neuron 2019; 101: 998-1002
• 38 Zheng H, Xu P, Jiang Q. et al. Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice. Microbiome 2021; 9: 145
• 39 Zhu X, Shen J, Feng S. et al. Akkermansia muciniphila, which is enriched in the gut microbiota by metformin, improves cognitive function in aged mice by reducing the proinflammatory cytokine interleukin-6. Microbiome 2023; 11: 120
• 40 Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease. Ageing Res Rev 2019; 54: 100936
• 41 Kullmann S, Kleinridders A, Small DM. et al. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol 2020; 8: 524-534
• 42 Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest 2016; 39: 1365-1376
• 43 Constantino LC, Binder LB, Vandresen-Filho S. et al. Role of phosphatidylinositol-3 kinase pathway in NMDA preconditioning: Different mechanisms for seizures and hippocampal neuronal degeneration induced by quinolinic acid. Neurotox Res 2018; 34: 452-462
• 44 James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol 2021; 22: 751-771
• 45 Kellar D, Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: Mechanisms and therapeutic approaches. Lancet Neurol 2020; 19: 758-766
• 46 Chen W, Cai W, Hoover B. et al. Insulin action in the brain: Cell types, circuits, and diseases. Trends Neurosci 2022; 45: 384-400
• 47 Ruegsegger GN, Vanderboom PM, Dasari S. et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight 2019; 4
• 48 Zheng T, Liu H, Qin L. et al. Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: Results from the GDMD study in China. Metabolism 2018; 87: 105-112
• 49 Davarpanah M, Shokri-Mashhadi N, Ziaei R. et al. A systematic review and meta-analysis of association between brain-derived neurotrophic factor and type 2 diabetes and glycemic profile. Sci Rep 2021; 11: 13773
• 50 Anita NZ, Zebarth J, Chan B. et al. Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. Brain Behav Immun 2022; 100: 55-69
• 51 Kong Y, Wang F, Wang J. et al. Pathological mechanisms linking diabetes mellitus and Alzheimer's disease: The receptor for advanced glycation end products (RAGE). Front Aging Neurosci 2020; 12: 217
• 52 Hoyos C, Colagiuri S, Turner A. et al. Brain oxidative stress and cognitive function in older adults with diabetes and pre-diabetes who are at risk for dementia. 2022; 184: 109178
• 53 Chitra L, Penislusshiyan S, Palvannan TJN. Astaxanthin-s-allyl cysteine diester against high glucose-induced neuronal toxicity in vitro and diabetes-associated cognitive decline in vivo: Effect on p53, oxidative stress and mitochondrial function. Neurotoxicology 2021; 86: 114-124
• 54 Tahira K, Sana K, Mohd A. et al. Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice. Neurochem Int 2021; 150: 105158
• 55 Karis L, María L-S, Sarah S. et al. Common pathways in dementia and diabetic retinopathy: Understanding the mechanisms of diabetes-related cognitive decline. Trends Endocrinol Metab 2021; 33: 50-71
• 56 Muriach M, Flores-Bellver M, Romero F. et al. Diabetes and the brain: Oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev 2014; 2014: 102158
• 57 Xiao C, Ademola CF, Jian T. et al. Hyperoside attenuates neuroinflammation, cognitive impairment and oxidative stress via suppressing TNF-α/NF-κB/caspase-3 signaling in type 2 diabetes rats. Nutr Neuroscience 2021; 25: 1774-1784
• 58 Bei-Ni W, Cheng-Biao W, Zi-Miao C. et al. DL-3-n-butylphthalide ameliorates diabetes-associated cognitive decline by enhancing PI3K/Akt signaling and suppressing oxidative stress. Acta Pharmacol Sin 2021; 42: 347-360
• 59 An J, Su J, Sun G. et al. Liraglutide alleviates cognitive deficit in db/db mice: Involvement in oxidative stress, iron overload, and ferroptosis. Neurochem Res 2021; 17: 2054-2081
• 60 Wanqiang W, Xin W, Qisen X. et al. Astaxanthin alleviates brain aging in rats by attenuating oxidative stress and increasing BDNF levels. Food Funct 2014; 5: 158-166
• 61 Reinhard J, Dirk FJN. Molecular machines governing exocytosis of synaptic vesicles. Nature 2012; 490: 201-207
• 62 Juan PH-F, Jaimar R, Adriana P. et al. Structural and ultrastructural analysis of cerebral cortex, cerebellum, and hypothalamus from diabetic rats. Exp Diabetes Res 2009; 2009: 329632
• 63 Toth CJHCN. Diabetes and neurodegeneration in the brain. Handb Clin Neurol 2014; 126: 489-511
• 64 Han C, Xiaokun G, Yujia L. et al. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. Am J Physiol Endocrinol Metab 2019; 318: E750-E764
• 65 Kumi H, Soichi K, Toru Y. et al. Association of cognitive dysfunction with hippocampal atrophy in elderly Japanese people with type 2 diabetes. Diabetes Res Clin Pract 2011; 94: 180-185
• 66 Lin Y, Meng-Yuan L, Kang-Cheng W. et al. Abnormal resting-state functional connectivity of hippocampal subregions in type 2 diabetes mellitus-associated cognitive decline. Front Psychiatry 2024; 15: 1360623
• 67 Pomilio C, Pérez NG, Calandri I. et al. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: Data from ADNI study. Geroscience 2022; 44: 1791-1805
• 68 Bailey CJ. Metformin: Historical overview. Diabetologia 2017; 60: 1566-1576
• 69 Secnik J, Xu H, Schwertner E. et al. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia. Alzheimers Res Ther 2021; 13: 197
• 70 Wu CY, Ouk M, Wong YY. et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status. Alzheimers Dement 2020; 16: 1663-1673
• 71 Kodali M, Attaluri S, Madhu LN. et al. Metformin treatment in late middle age improves cognitive function with alleviation of microglial activation and enhancement of autophagy in the hippocampus. Aging Cell 2021; 20: e13277
• 72 Samaras K, Makkar S, Crawford JD. et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020; 43: 2691-2701
• 73 Lu XY, Huang S, Chen QB. et al. Metformin ameliorates Aβ pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer's disease. Oxid Med Cell Longev 2020; 2020: 2315106
• 74 Yassine HN, Solomon V, Thakral A. et al. Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists. Alzheimers Dement 2022; 18: 478-497
• 75 Salles GN, Calió ML, Hölscher C. et al. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. Neuropharmacology 2020; 162: 107813
• 76 Zheng J, Xie Y, Ren L. et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease. Mol Metab 2021; 47: 101180
• 77 Wiciński M, Socha M, Malinowski B. et al. Liraglutide and its neuroprotective properties-focus on possible biochemical mechanisms in Alzheimer's disease and cerebral ischemic events. Int J Mol Sci 2019; 20: 1050
• 78 Vargas-Soria M, Carranza-Naval MJ, Del Marco A. et al. Role of liraglutide in Alzheimer's disease pathology. Alzheimers Res Ther 2021; 13: 112
• 79 Zhang Y, Xie JZ, Xu XY. et al. Liraglutide ameliorates jhperhomocysteinemia-induced Alzheimer-like pathology and memory deficits in rats via multi-molecular targeting. Neurosci Bull 2019; 35: 724-734
• 80 Duarte AI, Candeias E, Alves IN. et al. Liraglutide protects against brain amyloid-β(1-42) accumulation in female mice with early Alzheimer's disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation. Int J Mol Sci 2020; 21
• 81 Femminella GD, Frangou E, Love SB. et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study). Trials 2019; 20: 191
• 82 Kong FJ, Wu JH, Sun SY. et al. Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes. Neuropharmacology 2018; 131: 316-325
• 83 Yang Y, Fang H, Xu G. et al. Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats. Mol Med Rep 2018; 18: 2449-2257
• 84 Pawlos A, Broncel M, Woźniak E. et al. Neuroprotective effect of SGLT2 inhibitors. Molecules 2021; 26: 7213
• 85 Hayden MR, Grant DG, Aroor AR. et al. Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db/db mouse. Brain Sci 2019; 9: 57
• 86 Mone P, Lombardi A, Gambardella J. et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 2022; 45: 1247-1251
• 87 Hierro-Bujalance C, Infante-Garcia C, Del Marco A. et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimers Res Ther 2020; 12: 40
• 88 Lee N, Heo YJ, Choi SE. et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J Immunol Res 2021; 2021: 9944880
• 89 Gaire BP, Bae YJ, Choi JW. S1P(1) regulates M1/M2 polarization toward brain injury after transient focal cerebral ischemia. Biomol Ther 2019; 27: 522-529
• 90 Fagan SG, Bechet S, Dev KK. Fingolimod rescues memory and improves pathological hallmarks in the 3xTg-AD model of Alzheimer's disease. Mol Neurobiol 2022; 59: 1882-1895
• 91 Carreras I, Aytan N, Choi JK. et al. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Sci Rep 2019; 9: 10972
• 92 Sood A, Fernandes V, Preeti K. et al. Fingolimod alleviates cognitive deficit in type 2 diabetes by promoting microglial M2 polarization via the pSTAT3-jmjd3 axis. Mol Neurobiol 2023; 60: 901-922
• 93 Iwashita H, Matsumoto Y, Maruyama Y. et al. The melatonin metabolite N1-acetyl-5-methoxykynuramine facilitates long-term object memory in young and aging mice. J Pineal Res 2021; 70: e12703
• 94 Sumsuzzman DM, Choi J, Jin Y. et al. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev 2021; 127: 459-473
• 95 Xu J, Gao H, Zhang L. et al. Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high-fat diet. J Pineal Res 2019; 67: e12584
• 96 Chen C, Yang C, Wang J. et al. Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease. J Pineal Res 2021; 71: e12774
• 97 Vloemans AF, Eilander MMA, Rotteveel J. et al. Youth with type 1 diabetes taking responsibility for self-management: The importance of executive functioning in achieving glycemic control: Results from the Longitudinal DINO Study. Diabetes Care 2019; 42: 225-231
• 98 Srikanth V, Sinclair AJ, Hill-Briggs F. et al. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020; 8: 535-545
• 99 Zare S, Ostovarfar J, Kaveh MH. et al. Effectiveness of theory-based diabetes self-care training interventions; a systematic review. Diabetes Metab Syndr 2020; 14: 423-433
• 100 Varady KA, Cienfuegos S, Ezpeleta M. et al. Clinical application of intermittent fasting for weight loss: Progress and future directions. Nat Rev Endocrinol 2022; 18: 309-321
• 101 Dias GP, Murphy T, Stangl D. et al. Intermittent fasting enhances long-term memory consolidation, adult hippocampal neurogenesis, and expression of longevity gene Klotho. Mol Psychiatry 2021; 26: 6365-6379
• 102 Liu Y, Cheng A, Li YJ. et al. SIRT3 mediates hippocampal synaptic adaptations to intermittent fasting and ameliorates deficits in APP mutant mice. Nat Commun 2019; 10: 1886
• 103 Cignarella F, Cantoni C, Ghezzi L. et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab 2018; 27: 1222-1235.e6
• 104 Liu Z, Dai X, Zhang H. et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun 2020; 11: 855
• 105 Pitcher D, Parkin B, Walsh V. Transcranial magnetic stimulation and the understanding of behavior. Annu Rev Psychol 2021; 72: 97-121
• 106 Weiler M, Stieger KC, Long JM. et al. Transcranial magnetic stimulation in Alzheimer's disease: Are we ready?. eNeuro 2020; 7: 1-11
• 107 Chou YH, Sundman M, Ton That V. et al. Cortical excitability and plasticity in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies. Ageing Res Rev 2022; 79: 101660
• 108 Sabbagh M, Sadowsky C, Tousi B. et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. Alzheimers Dement 2020; 16: 641-650
• 109 Weiler M, Moreno-Castilla P, Starnes HM. et al. Effects of repetitive transcranial magnetic stimulation in aged rats depend on pre-treatment cognitive status: Toward individualized intervention for successful cognitive aging. Brain Stimul 2021; 14: 1219-1225
• 110 Teselink J, Bawa KK, Koo GK. et al. Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. Ageing Res Rev 2021; 72: 101499
• 111 Gomes-Osman J, Indahlastari A, Fried PJ. et al. Non-invasive brain stimulation: Probing intracortical circuits and improving cognition in the aging brain. Front Aging Neurosci 2018; 10: 177
• 112 Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2020; 86: 1-10
• 113 Li K, Wang X, Jiang Y. et al. Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice. J Psychiatr Res 2021; 136: 204-216
• 114 Cao H, Zuo C, Gu Z. et al. High frequency repetitive transcranial magnetic stimulation alleviates cognitive deficits in 3xTg-AD mice by modulating the PI3K/Akt/GLT-1 axis. Redox Biol 2022; 54: 102354

Publikationsverlauf

Eingereicht: 06. August 2024

Angenommen nach Revision: 21. November 2024

Accepted Manuscript online:
21. November 2024

Artikel online veröffentlicht:
13. Januar 2025